

**Maricopa Integrated Health Systems
Formulary Prior Auth Criteria**

Drug: Synagis (Palivizumab)

Therapy:

Is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD) and infants with a history of prematurity (≤ 35 weeks gestational age)

Inclusions:

- A) Patient is 24 months of age or less
- B) Does the patient have a significant risk of developing complications related to respiratory syncytial virus (RSV) infection (e.g. prematurity, bronchopulmonary dysplasia, immunocompromised)
- C) Children with BPD and/or prematurity and who also have asymptomatic acyanotic CHD (congenital heart disease) may benefit from prophylaxis
- D) Children with severe combined immunodeficiency or severe acquired immunodeficiency syndrome may benefit
- E) Drug request is to be given between October to April 30th

Exclusions:

Children with congenital heart disease, including cyanotic CHD

Authorization;

Between October to April 30th

Medical Director _____

Date _____